Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-02

AUTHORS

Andreas Körber, Charis Papavassilis, Vaishali Bhosekar, Maximilian Reinhardt

ABSTRACT

BACKGROUND: Psoriasis is a chronic inflammatory skin disease, affecting patients of a wide age range, including elderly patients. Elderly patients can respond differently to drug treatments and can be more vulnerable to adverse reactions. There are limited data on biologic therapies for psoriasis in elderly subjects. Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has proven significant efficacy in the treatment of moderate to severe psoriasis. AIMS: A post-hoc analysis of three phase III trials (ERASURE, FIXTURE and CLEAR) was performed to evaluate the efficacy and safety of secukinumab in elderly subjects. METHODS: Studies were multicentre, randomized, parallel-group, double-blind, 52-week phase III trials in subjects with moderate to severe plaque psoriasis. For efficacy analyses, 67 elderly subjects (≥ 65 years) treated with secukinumab 300 mg were compared with 841 younger subjects (18-64 years). Psoriasis Area and Severity Index (PASI), Dermatological Life Quality Index (DLQI) and safety were analysed. RESULTS: Elderly subjects had higher baseline frequencies of cardiovascular and metabolic disorders. Secukinumab efficacy in elderly subjects was comparable to that in younger subjects throughout 52 weeks of treatment. PASI 75 response was reached by 81.8% of elderly subjects and 79.4% of younger subjects at Week 52. Similar rates of DLQI 0/1 response were observed. The total rate of adverse events was similar between elderly and younger subjects. CONCLUSIONS: Secukinumab at the recommended dose (300 mg) is effective and acceptably safe in subjects aged ≥ 65 years with moderate to severe psoriasis, with quality-of-life benefits, despite an increased prevalence of cardiovascular and metabolic comorbidities in this population. More... »

PAGES

135-144

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40266-018-0520-z

DOI

http://dx.doi.org/10.1007/s40266-018-0520-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1100822287

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29404966


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chronic Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials, Phase III as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interleukin-17", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multicenter Studies as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Psoriasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Severity of Illness Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Essen University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.410718.b", 
          "name": [
            "Department of Dermatology, University Hospital Essen (A\u00f6R), Hufelandstra\u00dfe 55, 45147, Essen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "K\u00f6rber", 
        "givenName": "Andreas", 
        "id": "sg:person.01145551610.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145551610.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Papavassilis", 
        "givenName": "Charis", 
        "id": "sg:person.0716272754.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716272754.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (India)", 
          "id": "https://www.grid.ac/institutes/grid.464975.d", 
          "name": [
            "Novartis Healthcare Pvt. Ltd., Hyderabad, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bhosekar", 
        "givenName": "Vaishali", 
        "id": "sg:person.013137310337.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013137310337.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.467675.1", 
          "name": [
            "Novartis Pharma GmbH, Nuremberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reinhardt", 
        "givenName": "Maximilian", 
        "id": "sg:person.011331407423.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011331407423.03"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1111/jdv.12850", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000838975"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jaad.2015.05.013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003378700"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40266-014-0156-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004634174", 
          "https://doi.org/10.1007/s40266-014-0156-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.det.2014.09.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004745752"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2230.1994.tb01167.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006462973"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000345623", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009856056"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/circulationaha.109.192644", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011029623"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-013-0025-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012014989", 
          "https://doi.org/10.1007/s40259-013-0025-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jaad.2015.04.011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012031820"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bjd.13814", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012326879"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002512-200623030-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018677119", 
          "https://doi.org/10.2165/00002512-200623030-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jaad.2016.08.008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025225587"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/scitranslmed.3001107", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026879172"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/scitranslmed.3001107", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026879172"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/09546634.2013.865009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028559094"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/jdv.14115", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030513281"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1412679", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035341201"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/jdv.13354", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035498917"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/ard.2004.033217", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035667423"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bjd.12110", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041637344"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archdermatol.2010.186", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041812544"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1314258", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049860938"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/1346-8138.12653", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052373019"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-02", 
    "datePublishedReg": "2018-02-01", 
    "description": "BACKGROUND: Psoriasis is a chronic inflammatory skin disease, affecting patients of a wide age range, including elderly patients. Elderly patients can respond differently to drug treatments and can be more vulnerable to adverse reactions. There are limited data on biologic therapies for psoriasis in elderly subjects. Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has proven significant efficacy in the treatment of moderate to severe psoriasis.\nAIMS: A post-hoc analysis of three phase III trials (ERASURE, FIXTURE and CLEAR) was performed to evaluate the efficacy and safety of secukinumab in elderly subjects.\nMETHODS: Studies were multicentre, randomized, parallel-group, double-blind, 52-week phase III trials in subjects with moderate to severe plaque psoriasis. For efficacy analyses, 67 elderly subjects (\u2265\u00a065\u00a0years) treated with secukinumab 300\u00a0mg were compared with 841 younger subjects (18-64\u00a0years). Psoriasis Area and Severity Index (PASI), Dermatological Life Quality Index (DLQI) and safety were analysed.\nRESULTS: Elderly subjects had higher baseline frequencies of cardiovascular and metabolic disorders. Secukinumab efficacy in elderly subjects was comparable to that in younger subjects throughout 52\u00a0weeks of treatment. PASI 75 response was reached by 81.8% of elderly subjects and 79.4% of younger subjects at Week 52. Similar rates of DLQI 0/1 response were observed. The total rate of adverse events was similar between elderly and younger subjects.\nCONCLUSIONS: Secukinumab at the recommended dose (300\u00a0mg) is effective and acceptably safe in subjects aged \u2265\u00a065\u00a0years with moderate to severe psoriasis, with quality-of-life benefits, despite an increased prevalence of cardiovascular and metabolic comorbidities in this population.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s40266-018-0520-z", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1100990", 
        "issn": [
          "1170-229X", 
          "1179-1969"
        ], 
        "name": "Drugs & Aging", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "35"
      }
    ], 
    "name": "Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies", 
    "pagination": "135-144", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "8adde5f4c1dd468f8da01a1e657c0c1f964649c3bf1b01d8b84f06018e2da4db"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29404966"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9102074"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40266-018-0520-z"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1100822287"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40266-018-0520-z", 
      "https://app.dimensions.ai/details/publication/pub.1100822287"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T00:12", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8695_00000493.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s40266-018-0520-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40266-018-0520-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40266-018-0520-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40266-018-0520-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40266-018-0520-z'


 

This table displays all metadata directly associated to this object as RDF triples.

224 TRIPLES      21 PREDICATES      65 URIs      35 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40266-018-0520-z schema:about N10588e2bf9f94eed868a5a1bd3e7c425
2 N2e25414f97894d54aa2bb5394dce75ae
3 N2f64e44a30a34465b247a4ab6e9e39d9
4 N32619316ff254f488b83759ce5fee3d7
5 N3d216a3e3bb04d01a109915c968ab486
6 N4e21832fbca548a29b644aab4ebf2d7f
7 N69f9e800ffb9490eab8eff55457b9735
8 N8491fe984e8f4c468968c86db1a33b3c
9 N9ea9634bda014c459dbef88419e7275d
10 Ncb5b0d128eaf490b8764edb7836bdc4d
11 Ne54a0e16cd9847c0a3544f68b7962b73
12 Ne7d19d18e31041309f217ee125386791
13 Ned95a86daa5842f88963fdbfc7e6e597
14 Nfdc3d43bc3bb465da838ddd820cb6e73
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author N17b84251019f4f81bf532686a2f5ac17
18 schema:citation sg:pub.10.1007/s40259-013-0025-6
19 sg:pub.10.1007/s40266-014-0156-6
20 sg:pub.10.2165/00002512-200623030-00003
21 https://doi.org/10.1001/archdermatol.2010.186
22 https://doi.org/10.1016/j.det.2014.09.004
23 https://doi.org/10.1016/j.jaad.2015.04.011
24 https://doi.org/10.1016/j.jaad.2015.05.013
25 https://doi.org/10.1016/j.jaad.2016.08.008
26 https://doi.org/10.1056/nejmoa1314258
27 https://doi.org/10.1056/nejmoa1412679
28 https://doi.org/10.1111/1346-8138.12653
29 https://doi.org/10.1111/bjd.12110
30 https://doi.org/10.1111/bjd.13814
31 https://doi.org/10.1111/j.1365-2230.1994.tb01167.x
32 https://doi.org/10.1111/jdv.12850
33 https://doi.org/10.1111/jdv.13354
34 https://doi.org/10.1111/jdv.14115
35 https://doi.org/10.1126/scitranslmed.3001107
36 https://doi.org/10.1136/ard.2004.033217
37 https://doi.org/10.1159/000345623
38 https://doi.org/10.1161/circulationaha.109.192644
39 https://doi.org/10.3109/09546634.2013.865009
40 schema:datePublished 2018-02
41 schema:datePublishedReg 2018-02-01
42 schema:description BACKGROUND: Psoriasis is a chronic inflammatory skin disease, affecting patients of a wide age range, including elderly patients. Elderly patients can respond differently to drug treatments and can be more vulnerable to adverse reactions. There are limited data on biologic therapies for psoriasis in elderly subjects. Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has proven significant efficacy in the treatment of moderate to severe psoriasis. AIMS: A post-hoc analysis of three phase III trials (ERASURE, FIXTURE and CLEAR) was performed to evaluate the efficacy and safety of secukinumab in elderly subjects. METHODS: Studies were multicentre, randomized, parallel-group, double-blind, 52-week phase III trials in subjects with moderate to severe plaque psoriasis. For efficacy analyses, 67 elderly subjects (≥ 65 years) treated with secukinumab 300 mg were compared with 841 younger subjects (18-64 years). Psoriasis Area and Severity Index (PASI), Dermatological Life Quality Index (DLQI) and safety were analysed. RESULTS: Elderly subjects had higher baseline frequencies of cardiovascular and metabolic disorders. Secukinumab efficacy in elderly subjects was comparable to that in younger subjects throughout 52 weeks of treatment. PASI 75 response was reached by 81.8% of elderly subjects and 79.4% of younger subjects at Week 52. Similar rates of DLQI 0/1 response were observed. The total rate of adverse events was similar between elderly and younger subjects. CONCLUSIONS: Secukinumab at the recommended dose (300 mg) is effective and acceptably safe in subjects aged ≥ 65 years with moderate to severe psoriasis, with quality-of-life benefits, despite an increased prevalence of cardiovascular and metabolic comorbidities in this population.
43 schema:genre research_article
44 schema:inLanguage en
45 schema:isAccessibleForFree true
46 schema:isPartOf N6fcb454ca5ce4dfaad105442ac748e87
47 Nf55cdb73e05d4dbbaea7c1e5d778db69
48 sg:journal.1100990
49 schema:name Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies
50 schema:pagination 135-144
51 schema:productId N6ab55bd82eb24525bf1e6c5924b833cb
52 N74fa82678fb24acf8ddfaebb014fb1dc
53 N899df1a5c5ed413a9ff7353b577d3339
54 N97dad8abd09f4947ac53b596cd87519b
55 N9fd7487fac7146f2bc6268c1b0168e1a
56 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100822287
57 https://doi.org/10.1007/s40266-018-0520-z
58 schema:sdDatePublished 2019-04-11T00:12
59 schema:sdLicense https://scigraph.springernature.com/explorer/license/
60 schema:sdPublisher N4f68fbccd259409b91ce5907f2e63cfa
61 schema:url http://link.springer.com/10.1007/s40266-018-0520-z
62 sgo:license sg:explorer/license/
63 sgo:sdDataset articles
64 rdf:type schema:ScholarlyArticle
65 N10588e2bf9f94eed868a5a1bd3e7c425 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Antibodies, Monoclonal
67 rdf:type schema:DefinedTerm
68 N17b84251019f4f81bf532686a2f5ac17 rdf:first sg:person.01145551610.69
69 rdf:rest N49410fc4ba71468a8e6c1e6152c2fbc8
70 N2e25414f97894d54aa2bb5394dce75ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Humans
72 rdf:type schema:DefinedTerm
73 N2f64e44a30a34465b247a4ab6e9e39d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Female
75 rdf:type schema:DefinedTerm
76 N32619316ff254f488b83759ce5fee3d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Interleukin-17
78 rdf:type schema:DefinedTerm
79 N3d216a3e3bb04d01a109915c968ab486 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Male
81 rdf:type schema:DefinedTerm
82 N49410fc4ba71468a8e6c1e6152c2fbc8 rdf:first sg:person.0716272754.57
83 rdf:rest Nedce66ac85034b5c97eaa71e26d233c4
84 N4e21832fbca548a29b644aab4ebf2d7f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Treatment Outcome
86 rdf:type schema:DefinedTerm
87 N4f68fbccd259409b91ce5907f2e63cfa schema:name Springer Nature - SN SciGraph project
88 rdf:type schema:Organization
89 N69f9e800ffb9490eab8eff55457b9735 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Chronic Disease
91 rdf:type schema:DefinedTerm
92 N6ab55bd82eb24525bf1e6c5924b833cb schema:name readcube_id
93 schema:value 8adde5f4c1dd468f8da01a1e657c0c1f964649c3bf1b01d8b84f06018e2da4db
94 rdf:type schema:PropertyValue
95 N6fcb454ca5ce4dfaad105442ac748e87 schema:issueNumber 2
96 rdf:type schema:PublicationIssue
97 N74fa82678fb24acf8ddfaebb014fb1dc schema:name doi
98 schema:value 10.1007/s40266-018-0520-z
99 rdf:type schema:PropertyValue
100 N8491fe984e8f4c468968c86db1a33b3c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Severity of Illness Index
102 rdf:type schema:DefinedTerm
103 N899df1a5c5ed413a9ff7353b577d3339 schema:name dimensions_id
104 schema:value pub.1100822287
105 rdf:type schema:PropertyValue
106 N97dad8abd09f4947ac53b596cd87519b schema:name pubmed_id
107 schema:value 29404966
108 rdf:type schema:PropertyValue
109 N9e636d10cb4045d089e7de8c1ad99c65 rdf:first sg:person.011331407423.03
110 rdf:rest rdf:nil
111 N9ea9634bda014c459dbef88419e7275d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Randomized Controlled Trials as Topic
113 rdf:type schema:DefinedTerm
114 N9fd7487fac7146f2bc6268c1b0168e1a schema:name nlm_unique_id
115 schema:value 9102074
116 rdf:type schema:PropertyValue
117 Ncb5b0d128eaf490b8764edb7836bdc4d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Aged
119 rdf:type schema:DefinedTerm
120 Ne54a0e16cd9847c0a3544f68b7962b73 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Middle Aged
122 rdf:type schema:DefinedTerm
123 Ne7d19d18e31041309f217ee125386791 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Psoriasis
125 rdf:type schema:DefinedTerm
126 Ned95a86daa5842f88963fdbfc7e6e597 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Clinical Trials, Phase III as Topic
128 rdf:type schema:DefinedTerm
129 Nedce66ac85034b5c97eaa71e26d233c4 rdf:first sg:person.013137310337.01
130 rdf:rest N9e636d10cb4045d089e7de8c1ad99c65
131 Nf55cdb73e05d4dbbaea7c1e5d778db69 schema:volumeNumber 35
132 rdf:type schema:PublicationVolume
133 Nfdc3d43bc3bb465da838ddd820cb6e73 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Multicenter Studies as Topic
135 rdf:type schema:DefinedTerm
136 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
137 schema:name Medical and Health Sciences
138 rdf:type schema:DefinedTerm
139 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
140 schema:name Clinical Sciences
141 rdf:type schema:DefinedTerm
142 sg:journal.1100990 schema:issn 1170-229X
143 1179-1969
144 schema:name Drugs & Aging
145 rdf:type schema:Periodical
146 sg:person.011331407423.03 schema:affiliation https://www.grid.ac/institutes/grid.467675.1
147 schema:familyName Reinhardt
148 schema:givenName Maximilian
149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011331407423.03
150 rdf:type schema:Person
151 sg:person.01145551610.69 schema:affiliation https://www.grid.ac/institutes/grid.410718.b
152 schema:familyName Körber
153 schema:givenName Andreas
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145551610.69
155 rdf:type schema:Person
156 sg:person.013137310337.01 schema:affiliation https://www.grid.ac/institutes/grid.464975.d
157 schema:familyName Bhosekar
158 schema:givenName Vaishali
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013137310337.01
160 rdf:type schema:Person
161 sg:person.0716272754.57 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
162 schema:familyName Papavassilis
163 schema:givenName Charis
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716272754.57
165 rdf:type schema:Person
166 sg:pub.10.1007/s40259-013-0025-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012014989
167 https://doi.org/10.1007/s40259-013-0025-6
168 rdf:type schema:CreativeWork
169 sg:pub.10.1007/s40266-014-0156-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004634174
170 https://doi.org/10.1007/s40266-014-0156-6
171 rdf:type schema:CreativeWork
172 sg:pub.10.2165/00002512-200623030-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018677119
173 https://doi.org/10.2165/00002512-200623030-00003
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1001/archdermatol.2010.186 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041812544
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1016/j.det.2014.09.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004745752
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1016/j.jaad.2015.04.011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012031820
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1016/j.jaad.2015.05.013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003378700
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1016/j.jaad.2016.08.008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025225587
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1056/nejmoa1314258 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049860938
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1056/nejmoa1412679 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035341201
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1111/1346-8138.12653 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052373019
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1111/bjd.12110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041637344
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1111/bjd.13814 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012326879
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1111/j.1365-2230.1994.tb01167.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1006462973
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1111/jdv.12850 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000838975
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1111/jdv.13354 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035498917
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1111/jdv.14115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030513281
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1126/scitranslmed.3001107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026879172
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1136/ard.2004.033217 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035667423
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1159/000345623 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009856056
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1161/circulationaha.109.192644 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011029623
210 rdf:type schema:CreativeWork
211 https://doi.org/10.3109/09546634.2013.865009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028559094
212 rdf:type schema:CreativeWork
213 https://www.grid.ac/institutes/grid.410718.b schema:alternateName Essen University Hospital
214 schema:name Department of Dermatology, University Hospital Essen (AöR), Hufelandstraße 55, 45147, Essen, Germany
215 rdf:type schema:Organization
216 https://www.grid.ac/institutes/grid.419481.1 schema:alternateName Novartis (Switzerland)
217 schema:name Novartis Pharma AG, Basel, Switzerland
218 rdf:type schema:Organization
219 https://www.grid.ac/institutes/grid.464975.d schema:alternateName Novartis (India)
220 schema:name Novartis Healthcare Pvt. Ltd., Hyderabad, India
221 rdf:type schema:Organization
222 https://www.grid.ac/institutes/grid.467675.1 schema:alternateName Novartis (Germany)
223 schema:name Novartis Pharma GmbH, Nuremberg, Germany
224 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...